These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 27943166

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
    Piñana JL, Valcárcel D, Fernández-Avilés F, Martino R, Rovira M, Barba P, Martínez C, Brunet S, Sureda A, Carreras E, Sierra J.
    Bone Marrow Transplant; 2010 Sep; 45(9):1449-56. PubMed ID: 20140024
    [Abstract] [Full Text] [Related]

  • 27. Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan.
    Iida M, Fukuda T, Uchida N, Murata M, Aotsuka N, Minagawa K, Oohashi K, Fukushima K, Kondo T, Eto T, Miyamoto T, Morishima Y, Nagamura T, Atsuta Y, Suzuki R.
    Clin Transplant; 2014 Sep; 28(9):980-9. PubMed ID: 24943923
    [Abstract] [Full Text] [Related]

  • 28. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.
    Bornhäuser M, Schuler U, Pörksen G, Naumann R, Geissler G, Thiede C, Schwerdtfeger R, Ehninger G, Thiede HM.
    Transplantation; 1999 Feb 27; 67(4):499-504. PubMed ID: 10071016
    [Abstract] [Full Text] [Related]

  • 29. [Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation].
    Liu QF, Sun J, Zhang Y, Xu D, Liu XL, Xu B, Meng FY, Zhou SY.
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov 27; 23(11):1143-5. PubMed ID: 14625172
    [Abstract] [Full Text] [Related]

  • 30. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
    Jorge AS, Suárez-Lledó M, Pereira A, Gutierrez G, Fernández-Avilés F, Rosiñol L, Llobet N, Solano T, Urbano-Ispízua Á, Rovira M, Martínez C.
    Biol Blood Marrow Transplant; 2018 Jun 27; 24(6):1196-1202. PubMed ID: 29410343
    [Abstract] [Full Text] [Related]

  • 31. Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.
    Bejanyan N, Rogosheske J, DeFor TE, Lazaryan A, Arora M, Holtan SG, Jacobson PA, MacMillan ML, Verneris MR, Blazar BR, Weisdorf DJ, Wagner JE, Brunstein CG.
    Biol Blood Marrow Transplant; 2016 Nov 27; 22(11):2025-2030. PubMed ID: 27519278
    [Abstract] [Full Text] [Related]

  • 32. Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation.
    Yoshida S, Ohno Y, Nagafuji K, Yoshimoto G, Sugio T, Kamimura T, Ohta T, Takase K, Henzan H, Muta T, Iwasaki H, Ogawa R, Eto T, Akashi K, Miyamoto T.
    Ann Hematol; 2019 Nov 27; 98(11):2579-2591. PubMed ID: 31628517
    [Abstract] [Full Text] [Related]

  • 33. Phase I study of graft-versus-host disease prophylaxis including bortezomib for allogeneic hematopoietic cell transplantation from unrelated donors with one or two HLA loci mismatches in Japanese patients.
    Nakane T, Okamura H, Tagaito Y, Koh S, Yoshimura T, Makuuchi Y, Nanno S, Nakamae M, Hirose A, Nakashima Y, Koh H, Hino M, Nakamae H.
    Int J Hematol; 2019 Dec 27; 110(6):736-742. PubMed ID: 31560116
    [Abstract] [Full Text] [Related]

  • 34. Human herpesvirus 6 encephalitis in patients administered mycophenolate mofetil as prophylaxis for graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Inui Y, Yakushijin K, Okamura A, Tanaka Y, Shinzato I, Nomura T, Ichikawa H, Mizutani Y, Kitao A, Kurata K, Kakiuchi S, Miyata Y, Sanada Y, Kitagawa K, Uryu K, Kawamoto S, Yamamoto K, Matsuoka H, Murayama T, Ito M, Minami H.
    Transpl Infect Dis; 2019 Feb 27; 21(1):e13024. PubMed ID: 30414316
    [Abstract] [Full Text] [Related]

  • 35. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M, Militano O, Jin Z, Figurski M, Shaw L, Moore V, Morris E, Tallamy B, van deVen C, Ayello J, Baxter-Lowe L, Satwani P, George D, Bradley MB, Garvin J, Cairo MS.
    Biol Blood Marrow Transplant; 2010 Mar 27; 16(3):333-43. PubMed ID: 19835971
    [Abstract] [Full Text] [Related]

  • 36. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.
    Greco R, Lorentino F, Albanese S, Lupo Stanghellini MT, Giglio F, Piemontese S, Clerici D, Lazzari L, Marcatti M, Mastaglio S, Xue E, Farina F, Pavesi F, Assanelli A, Carrabba MG, Marktel S, Vago L, Bonini C, Corti C, Bernardi M, Ciceri F, Peccatori J.
    Transplant Cell Ther; 2021 Sep 27; 27(9):776.e1-776.e13. PubMed ID: 34087452
    [Abstract] [Full Text] [Related]

  • 37. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.
    Lazaryan A, Weisdorf DJ, DeFor T, Brunstein CG, MacMillan ML, Bejanyan N, Holtan S, Blazar BR, Wagner JE, Arora M.
    Biol Blood Marrow Transplant; 2016 Jan 27; 22(1):134-40. PubMed ID: 26365153
    [Abstract] [Full Text] [Related]

  • 38. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G, ATG-Fresenius Trial Group.
    Lancet Oncol; 2009 Sep 27; 10(9):855-64. PubMed ID: 19695955
    [Abstract] [Full Text] [Related]

  • 39. Enteric-coated mycophenolate sodium containing GvHD prophylaxis reduces GvHD rate after allogeneic HSCT.
    Weber T, Niestadtkötter J, Wienke A, Müller-Tidow C, Müller LP.
    Eur J Haematol; 2016 Sep 27; 97(3):232-8. PubMed ID: 26613546
    [Abstract] [Full Text] [Related]

  • 40. Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors.
    Montoro J, Piñana JL, Hernández-Boluda JC, Hernani R, Lorenzo I, Pérez A, Guerreiro M, Balaguer-Rosello A, Sanz GF, Carretero C, Albert E, Navarro D, Sanz MA, Solano C, Sanz J.
    Bone Marrow Transplant; 2020 Nov 27; 55(11):2147-2159. PubMed ID: 32371901
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.